Together, these data suggested that BM microenvironment potently induced CML CD34+ cells resistance, leading to the failure of clinically-available BCR-ABL TKIs in eradicating minimal residual disease. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.